BerGenBio Second Quarter Outcomes 2024: Strong medical and monetary progress By Investing.com

BERGEN, Norway, Aug. 21, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical firm creating novel, selective AXL kinase inhibitors for extreme unmet medical wants, as we speak introduced monetary outcomes for the quarter and half 12 months ended June 30, 2024, and offered a enterprise replace.

Highlights, together with submit interval:

• BGBC016 1L NSCLC STK11m examine continues to progress as deliberate. Enrollment within the Ph1b half accomplished. Knowledge Security Monitoring Board evaluate of information from the ultimate Ph1b dose cohort helps security and tolerability of the mix of bemcentinib with customary of care chemo/immunotherapy permitting initiation of the two^nd dose within the Ph2a half. All Ph2a websites have now been activated.
• Progressive strategy established with main genomic AI supplier to speed up growth of bemcentinib. Established knowledge and regulatory collaboration with expertise firm Tempus AI (Nasdaq: TEM) to offer potential comparative medical knowledge from 1L STK11m NSCLC sufferers to assist within the analysis of BGBC016 outcomes.
• Strengthened monetary place. Secured gross funding of NOK 138.9 million from warrant train in June 2024 securing funding into H2 2025. Monetary place of NOK 200.1 million finish of Q2 2024.
• Secure money use. Continued decreased and stabilized working bills at NOK 90.5 million for first half 2024 in comparison with NOK 120.2 million in first half 2023. Working bills NOK 50.8 million in Q2 2024 in comparison with NOK 47.8 million in Q2 2023.

Martin Olin (NYSE:), Chief Government Officer of BerGenBio said:

“The BGBC016 clinical trial continued to progress well during the quarter. An independent review of the final cohort in the Ph1b part showed acceptable safety allowing initiation of the 2^nd dose in the Ph2a part, and we completed the activation of the Ph2a sites. We now look forward to sharing preliminary efficacy data from the Ph2a portion of the study as they mature. During the quarter we strengthened our financial position which will, combined with our continuing cost discipline, fund our planned activities into the second half of 2025. The BGBC016 clinical trial is our highest priority, and we remain dedicated to unlocking the significant value potential in bemcentinib.”

Presentation and Monetary Report

The Q2 2024 Monetary report is hooked up to this inventory change announcement and the report and the Q2 2024 presentation can be found on the Firm’s web site https://www.bergenbio.com/buyers/financial-reports.

Webcast particulars

BerGenBio’s senior administration workforce will present a enterprise replace as we speak at 9:45 am CET. The presentation will webcast reside. To take part within the webcast, please use the next hyperlink:

https://channel.royalcast.com/landingpage/hegnarmedia/20240821_12/

A recording of the webcast can be obtainable at www.bergenbio.com within the Buyers/Monetary Stories part  (https://www.bergenbio.com/buyers/financial-reports) shortly afterwards.

Contacts

Martin Olin CEO,  BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Media Relations

Jan Lillebyjl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical firm centered on creating transformative medicine concentrating on AXL as a possible cornerstone of remedy for aggressive ailments, together with most cancers and extreme respiratory infections. The Firm is targeted on its proprietary lead candidate, bemcentinib, a probably first-in-class selective AXL inhibitor in medical growth for STK11 mutated NSCLC and preclinical growth for extreme respiratory infections.

BerGenBio is predicated in Bergen, Norway, with a subsidiary in Oxford, UK. The corporate is listed on the Oslo Inventory Trade (ticker: BGBIO). For extra data, go to www.bergenbio.com

Ahead trying statements

This announcement could include forward-looking statements, which as such will not be historic information, however are based mostly upon varied assumptions, lots of that are based mostly, in flip, upon additional assumptions. These assumptions are inherently topic to important identified and unknown dangers, uncertainties, and different essential components. Such dangers, uncertainties, contingencies and different essential components may trigger precise occasions to vary materially from the expectations expressed or implied on this announcement by such forward-looking statements.

This data is taken into account to be inside data pursuant to the EU Market Abuse Regulation and topic to the disclosure necessities pursuant to part 5-12 of the Norwegian Securities Buying and selling Act.

This data was delivered to you by Cision http://information.cision.com

https://information.cision.com/bergenbio-asa/r/bergenbio-second-quarter-results-2024–solid-clinical-and-financial-progress,c4026515

The next information can be found for obtain: